The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•20 March 2026•

1 min read

IBA and Telix Partner to Expand Radiopharmaceutical Production in the US

An illustration of a global supply chain with factories, labs, and shipping containers on a world map, showing warning signs, red lights, and text 'production' and 'توقف' (stop).

Key Facts

1IBA signed a contract with Telix Pharmaceuticals for the initial order of four Cyclone KIUBE cyclotrons.

IBA (Ion Beam Applications S.A.) has signed a strategic contract with Telix Pharmaceuticals to supply four Cyclone KIUBE cyclotrons to bolster production capacity. These advanced systems are scheduled for installation at selected RLS Radiopharmacies (RLS) facilities across the United States. The agreement marks a significant step in Telix's strategy to expand its manufacturing footprint for precision oncology treatments within the U.S. market. By increasing production capacity, Telix aims to accelerate the development and distribution of innovative nuclear medicine solutions. For IBA, the deal represents a confirmed equipment sale and reinforces its position as a leading provider of radiopharmaceutical technology. This partnership reflects positive operational momentum for both companies as they address the growing demand in the oncology sector.